Rapid Symptomatic Improvement in Gefitinib-Treated Patients with EGFR-Mutated Lung Cancer: Possible Role of Downregulation of Inflammatory Molecules?-Reference-Cited by-同舟云学术

Rapid Symptomatic Improvement in Gefitinib-Treated Patients with EGFR-Mutated Lung Cancer: Possible Role of Downregulation of Inflammatory Molecules?

Published:2011 Issue:10 Volume:34 Page:559-560
ISSN:1423-0240
Container-title:Onkologie
language:en
Short-container-title:Onkologie

Author:

Suspitsin Evgeny N.,Levchenko Evgeny V.,Moiseyenko Fedor V.,Ivantsov Alexandr O.,Radzhabova Samira A.,Matsko Dmitry E.,Moiseyenko Vladimir M.,Imyanitov Evgeny N.

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference9 articles.

1. EGFR-targeted therapies in lung cancer: predictors of response and toxicity

2. High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma

3. Gefitinib in patients with non-small cell lung cancer: Symptomatic improvement within a few days

4. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

5. MMP-12 induces IL-8/CXCL8 secretion through EGFR and ERK1/2 activation in epithelial cells

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Up-Regulation of Transient Receptor Potential Melastatin 6 Channel Expression by Tumor Necrosis Factor-α in the Presence of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor;Journal of Cellular Physiology;2017-04-25

2. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study;Lung Cancer;2013-08

3. The individualization of treatment based on molecular markers;memo - Magazine of European Medical Oncology;2012-11-15